No Data
No Data
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6
Piper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?
Akebia Therapeutics Announces Public Offering Pricing
12 Health Care Stocks Moving In Thursday's Intraday Session